US 11,717,519 B2
Use of fatty acid oxidation inhibitors as antimicrobials
Jennifer A. Philips, St. Louis, MO (US); Kathryn Moore, New York, NY (US); Pallavi Chandra, St. Louis, MO (US); and Mireille Ouimet, New York, NY (US)
Assigned to Washington University in St. Louis, St. Louis, MO (US); and New York University, New York, NY (US)
Appl. No. 16/979,443
Filed by Washington University in St. Louis, St. Louis, MO (US); and New York University, New York, NY (US)
PCT Filed Mar. 15, 2019, PCT No. PCT/US2019/022457
§ 371(c)(1), (2) Date Sep. 9, 2020,
PCT Pub. No. WO2019/178472, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/644,105, filed on Mar. 16, 2018.
Prior Publication US 2021/0000821 A1, Jan. 7, 2021
Int. Cl. A61K 31/495 (2006.01); A61K 31/336 (2006.01); A61K 45/06 (2006.01); A61K 31/198 (2006.01); A61K 31/352 (2006.01); A61K 31/365 (2006.01); A61K 31/4453 (2006.01); A61K 31/155 (2006.01)
CPC A61K 31/495 (2013.01) [A61K 31/198 (2013.01); A61K 31/336 (2013.01); A61K 31/352 (2013.01); A61K 31/365 (2013.01); A61K 31/4453 (2013.01); A61K 31/155 (2013.01); A61K 45/06 (2013.01)] 17 Claims
 
1. A method of treating Mycobacteria infection in a subject in need thereof, the method comprising administering a fatty acid oxidase (FAO) inhibitor to the subject, wherein the FAO inhibitor is etomoxir.